Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study

BACKGROUND: Indolent systemic mastocytosis, including the subvariant of smouldering systemic mastocytosis, is a lifelong condition associated with reduced quality of life. Masitinib inhibits KIT and LYN kinases that are involved in indolent systemic mastocytosis pathogenesis. We aimed to assess safe...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
الحاوية / القاعدة:Lancet
المؤلفون الرئيسيون: Lortholary, Olivier, Chandesris, Marie Olivia, Livideanu, Cristina Bulai, Paul, Carle, Guillet, Gérard, Jassem, Ewa, Niedoszytko, Marek, Barete, Stéphane, Verstovsek, Srdan, Grattan, Clive, Damaj, Gandhi, Canioni, Danielle, Fraitag, Sylvie, Lhermitte, Ludovic, Lavialle, Sophie Georgin, Frenzel, Laurent, Afrin, Lawrence B, Hanssens, Katia, Agopian, Julie, Gaillard, Raphael, Kinet, Jean-Pierre, Auclair, Christian, Mansfield, Colin, Moussy, Alain, Dubreuil, Patrice, Hermine, Olivier
التنسيق: Artigo
اللغة:Inglês
منشور في: 2017
الموضوعات:
Article
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC5985971/
https://ncbi.nlm.nih.gov/pubmed/28069279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)31403-9
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة